READ MORE

Mechanism

Key Features

Differentiation

Preclinical Highlights

cilon | ACCESS ASIA BD Forum @JPM 2026

The Blueprint:

A Portfolio of Executed Programs

READ MORE

www.medicilon.com

COMPANY PROFILE

From its inception in 2004, Medicilon (SHA: 688202) has been committed to providing comprehensive research and development (R&D) services to biopharmaceutical companies, research institutions, and other organizations working in the preclinical space, with the primary objective of supporting and accelerating pharmaceutical, bio-pharmaceutical and medical device R&D worldwide.

SERVICE SCOPE

Drug Discovery
- Chemistry
- Biology
- Early DMPK

Drug Development & CMC
- API/Formulation
- CMC Research

Preclinical Research
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Drug Safety Evaluation
- Bioanalysis

IND Filing
- FDA
- NMPA
- EMA
- TGA
- MFDS
- PMDA



MEDICILON

Email: marketing@medicilon.com **Website:** www.medicilon.com

USA: 20 Maguire Road, Suite 103, Lexington, MA 02421, USA

China: 585 Chuanda Road, Pudong, Shanghai, 201299, China

15-PGDH inhibitor

A •= 9 Q t G€Ñ t 9 Đ Đt tgdÑS•Þ‘S•Đ&Q ªÒ 9 Đ Ú•% — Ý ! îÕt 9 Đ
Zhang et al. Science 2015; D.075017D011A01119 0 TD8(3)]TJ0.738 0 TD(62.075017D011A8.729 0 TD0); ( )B.

Lead Program - HW201877

A poten st in c therapy for ammatory bowe (IBD)

- **Di eren a**
  -
  -
  -
  -
- **Preclinical Highligh**
  -
  -
- **Planned Clinical Milest**
  -
  -
  -

DSS-induced IBD



TNBS-induced IBD



DSS-induced IBD



ABX464/Obefazimod is a phase 3 best-in-disease (miRNA modifier) oral drug candidate for IBD developed by Abivax

MRGPRX2 antagonist



Lead Program - HW281171

m m c for chronic spontaneous caria (CSU)

- **Di eren a**
  -
  -
  -
  -
- **Preclinical Highligh**
  -
  -
  -
  - *in vivo*
- **Planned Clinical Milest**
  -
  -

Passive Cutane us Anaphylaxis reac n (PCA)



Itch Behavi ral Study



Contact: David Wang, wangdaoyi@renfu.com.cn

P2X3 Receptor Inhibitor

- **Unmet Medical**
  -
  -
- **Mechanism Ac n**
  -
  -
  -
  -



Reference:
Guo et al. Nat Commun 14, 5844 (2023)
Zhang et al. Purinergic Signal. 2022 Sep;18(3):289-305.
Zang et al. Eur J Med Chem. 2025:300(118116)

Lead Program – HW091077

A poten best-in- therapy for refractory chronic cough (RCC)

- **Di eren a**
  -
  -
  -
  -
- **Preclinical Highligh**
  -
  -
  -
- **Planned Clinical Milest**
  -
  -
  -

Compound	Gefap



DILI: Drug-induced l



Contact: David Wang, wangdaoyi@renfu.com.cn

- **Mechanis**
  -

Contact: Subo Liao, subo.liao@humanwellus.com





Contact: Yingfu Li, yingfuli@hyperwaypharma.com

- -Ac n

BT-114143, a No and Potent Sm - c inogen Inhibitor for Hy ysis





Key Features

- Enhanced An ly Ac ity
- Minimized CNS Exp sure and GI side-e ects
- Intramuscular (IM) Administra Feasibility
  - ✓
  - ✓

Ex vivo Efficacy of BT-114143 and TXA in Human Whole Blood TEG Analysis (n=6)

Analyte	Mean IC_{50} (☒M)	Mean IC_{90} (☒M)
BT-114143	0.56	1.01
TXA	3.39	10.12

Phase I Study of Safety, T r y, Pharmacokine , and tory c E ects of Intravenous BT-114143 in H hy V nteers

- Purp e stud
- Trial design
- Highlights
  -
  -

Phase Ib nter, Randomized, Con ed, Dose-Esc Study of BT-114143 P nts with Uterine eding (AUB)

- Purp e stud
- Trial design ×
- Highlights
  -
  -
  -

Planned Clinical Milest es

-
-

Contact: Shaomei Zeng, shaomei.zeng@btyy.com

- Gluetacs Therapeutics is a biopharmaceutical company developing oral small-molecule targeted protein degraders.
- Seeking strategic partnerships for the development of its pipeline assets, including licensing, co-development, and/or collaborative opportunities.
- Headquarter: Shanghai, China

GlueTacs® Library

- A proprietary library of **over 13,000** small-molecule degraders, including **molecular glues and bifunctional modalities**
- **Mechanism:**
  - Molecular glues and bifunctional degraders recruit target proteins to E3 ligases
  - Ubiquitination marks the target protein for recognition and selective degradation by the proteasome
- **Key Features:**
  - Orally available small-molecule modality
  - Expands the druggable space
  - Novel scaffold design enables enhanced substrate selectivity and efficacy
  - Operates via catalytic "event-driven" pharmacology



Gluetacs Pipelines

- **GT919:** IKZF3/1 degrader
- **Indications:** Relapsed and Refractory Multiple Myeloma (r/r MM)
- **Stage:** Phase II Clinical Trials
- **Phase I Results:**
  - **Manageable Safety**
    - ✓ No DLTs were observed at all dose levels (0.5, 1, 2, 3, 4 and 5 mg).
    - ✓ No TEAEs or TRAEs led to GT919 discontinuation, dose reduction or death.
    - ✓ Wide safety dose range and promising safety profile.
  - **Encouraging Efficacy**
    - ✓ ORR of 50% among 10 evaluable triple-refractory patients that received GT919 at RP2D.



- **GT929:** IKZF3/1 degrader
- **Indications:** Relapsed and Refractory

Se -em fying Lipid Nanop e (SELNP) orm



- Key Features

Lead Program – MJC-001

- MJC-001 Oral Paclitaxel S gel Capsule N el Metr n mic Q3D high- requency and l -d sing regimen
- Indica ns Gastric, es phagus, NSCLC, breas varian, liver cancer and br arc ma
- Di eren a n

MJC-001 demonstrates exce ent therapeu e acy in mu PDX mouse s tumor mode







- Preclinical Highligh
- Planned Clinical Milest nes

Contact: Huiyu Huang, huiyu.huang@meijibiopharm.com

Category	Program	TA	Target/ Modality	Geography	Discovery	Preclinical	Phase I	Phase II	Phase III
ADC	ILB-3101	Oncology	B7H3-Eribulin ADC						
	ILB-3103	Oncology	DLL-3×B7H3 FIC BsADC						
	ILB-3203	Oncology	PD-L1×VEGF FIC BsADC						
IO	ILB-2109	Oncology	A2aR/Small molecule						
	ILB-2101	Oncology	CD40 Agonist mAb						
	ILB-2201	Oncology	PD-L1/VEGF BsAb						
Auto-immune	ILB-2107	Auto-Immune Diseases	OX40 antagonist						
	ILB-2110	Auto-Immune Diseases	PD-1 agonist mAb						
	ILB-2202	Auto-Immune Diseases	PD-1 Agonist/TNFα						

RabPharma C ., Ltd.

-licensing,
c -dev ment, g, mergers and acqui ns (M&A), equity investments,
j int clinical dev nt rch pr grams

An overview

- RabPharma

st cr is,
racture healing, st r is, and in at ry arthr including RA and OA
Our di er

➢ Target & Car ge Therap A First-in-Class Appr

➢ Unmet Medical -Surgical treatments st cr is
R ust and va ve Pipelin Phase I and II Trials
Rab-001

Rab-00

➢ Str g Gl Patent Pr t

Leading drug candidate

- *Rab-001: First-in- drug for osteonecrosis in humans*

Pre-clinical e cacy studies

coc -induced osteoporosis and osteonecrosis in mouse *Primary osteoporosis f strogen ciency* *Fracture he ing*







Rab-001 has exc nt safety and PK in c inic studies Phase I a & b Studies			
C ntry	Subject	S ety	PK
USA (NCT03197623)	59	Rab-001 was well t lerated ll wing mul d ses intraven us administr n in pateints n gluc c r id with b ne l ss. The number ubjects with TEAEs r seri us TEAEs was similar between the ac ve and placeb treatment gr ups.	Peak plasma c ncentr ns Rab-001 increased with the increase in d se,with the absence accumul n, and achievement steady state er 3 I.V. d ses.
China (CTR20222771)	16	Similar sa ety pr les were bserved in the healthy Chinese p pul n, with similar number subjects with TEAEs rep rted in either the ac ve r placeb treatment gr ups.	Similar PK pr les were bserved in Ph1 in China.The plasma c ncentr n he drug increased with increasing d sing,with the absence ccumul n ll wing I.V. injec ns.

Phase II Study (-trauma st cr is ral head) -g ing (CTR20244223)

- *Rab-001d: Poten to be the disease-modifying drug for OA*





Contact: JIWEI CHEN, jiwei@rabpharma.com

- Headquarters: Wuhan, China
- Committed to the discovery and development of antibody-based therapies (BsAb, ADC, BsAb-ADC, etc.) for the treatment of oncology and autoimmune diseases.
- Seeking for partnership for clinical development (licensing, co-development and/or collaboration) of multiple bispecific antibodies and ADCs in our pipeline.

VersatiBody Platform

Heart of Platform

Engineer and modify the structure of naturally occurring antibodies to optimize their function and binding affinity

Foundation

Distinct antibody structures and modality tailored for each specific disease, such strong adaptability enables the development of antibodies against a wide range of targets

Hanbio *VersatiBody*

Continuous Development

Modular Design

Incorporate modular design for the rapid assembly of new antibody constructs and easy antibody production and development

Workflow

- Target selection based on disease biology
- Molecular design per MoAs
- Manufacturability and stability validation



Note: illustrative purposes only.

Lead ADC Program – HX111

- HX111: a "FIC" ADC targeting OX40
- **Indications:** selected types of T-cell or B-cell lymphoma as well as certain types of solid tumors
- **Differentiation:**
  - A "FIC" OX40-ADC with dual-modalities: 1). ADC-based robust and durable anti-tumor effects on selected types of lymphoma (most PTCL) and solid tumors; 2). Immunotherapy for pan-solid tumors featured with potent Treg-depleting activities.
- **Target Biology**
  - Over-expressed in selected lymphoma and leukemia (L/L), including nearly all ATLL, AITL, NK/T, Histiocytic lymphoma, and some EBV+ DLBCLs, etc.
  - Also expressed in significant portion of solid tumors, e.g. selected types of H&NSCC, breast, cervical cancer
  - Little expression among normal tissues, including normal lymphocytes, with potentially minimal "off-target" toxicities.
- **Pharmacology Highlights:**
  - Potent efficacy in multiple OX40+ mouse models.
  - Confirmed potent Treg-depletion activities, enabling its anti-tumor immunity.
  - Similar spectrum of toxicities as other MMAE based ADC in cyno-monkeys, enabling easy toxicity management in clinical trials.
- **Planned Clinical Milestones:**
  - IND approved
  - FIH (Phase 1a/1b) in early 1Q 2026 (multi-center)
  - Combination options with other immunotherapies

HX111 is highly active in OX40+ tumors (ADC MoA)





Contact: Sabrina Wu, sabrina.wu@waterstonepharma.com

NLRP3 as a Therape Target

- **NLRP3 In a**
- **R es played by NLRP3 in CNS dis rders & CAPS** [1]
  - **neur n mmat ry and neur egenera ve dis rders**
  - **CAPS**
  - **signaling** **IL-1**



Lead Program – ZL-65

- **An ral, highly tent and highly selec ve, brain-penetrant NLRP3 in a e inhibit r with Best-In-Class ten al.**
- **Lead Indica n CAPS PD, MS, and ALS.**
- **suppressing the matura n and release IL-1 and IL-18**

- **Key Di eren a n**
  - **Structurally di eren ated, highly tent; brain-penetrant**
  - **Highly selec ve r NLRP3**
  - **Sa ety margin ~120×**
    10× wider therapeu c index than VTX3232
- **Preclinical Highlights**
  - **Br d se-dependent e cacy with nc nal bene ts av rable PK and sa ety margin**
  - **Best-in-class CNS exp sure**
  - **enc raging bi rker la n (e.g., CRP/IL-6) hist ath cal vements**
- **Planned Clinical Milest e**

ZL-65 Shows Neuroprotec ve E ects in SNpc of 6-OHDA PD Rat



Sham (contro)



Levodopa
15 mg/kg

ZL-65
100 mg/kg

Lev d pa as the re erence drug

Contact: Neil Wang, neilwang@zenitar.cn

Robust e

Type	Project	Indication	Lead	Preclinical	IND	Phase1	Phase2	Phase3	Launch
Biosimilar	Pegfilgrastim	Oncology							
Biosimilar	Insulin Glargine	Diabetes							
Biosimilar	Rituximab	Oncology							
TCE	F182112 (BCMA-CD3)	Oncology, AID							FDA IND Approval
Fusion	F008 (rNIF-NHH)*	AIS							
Fusion	F012 (PEG-UHC)*	Gout, HUA							
TCE	LNF2007 (Claudin18.2-CD3)	Oncology							FDA IND Approval
mAb	LNF2102 (FGFR2b)	Oncology							
TCE	LNF1904 (CD19-CD3)	Oncology, AID							FDA IND Approval
Fusion	LNF2003 (GLP1/FGF21)	MASH							
Protein	LNF2401 (KLK1)	AIS							
ADC	LNF2105 (NECTIN4)	Oncology							

*.F008 is Recombinant Neutrophil Inhibitory Factor and Hirulog Hybrid
F012 is PEG-Uricase of Human-Canine

SAFETY AND EFFICACY OF F182112 IN PATIENTS WITH RRMM

- Pr duct in ma n
- Clinical trial in ma
- Clinical c de name
- Manageable Sa ety Pr l
  -

	F182112-001		MajesTEC-1 (Tecvayli)		MagnetisMM-3 (Elranatamab)	
	All grade	≥Grade 3	All grade	≥Grade 3	All grade	≥Grade 3
	no. of patients (%)					
Any adverse event(TEAE)	107 (99.70)	100 (92.59)	165 (100)	156 (94.5)	123 (100)	87 (70.7)
Hematologic (≥20%)						
Neutropenia	75 (71.96)	61 (57.94)	120 (73.2)	106 (64.2)	80 (65.0)	60 (48.8)
Anemia	68 (65.35)	26 (24.30)	86 (52.1)	61 (37.0)	60 (48.8)	46 (37.4)
Thrombocytopenia	60 (57.81)	24 (22.64)	80 (48.5)	54 (32.7)	54 (43.9)	31 (25.2)
Lymphopenia	79 (73.83)	72 (67.29)	57 (34.5)	54 (32.7)	33 (26.8)	31 (25.2)
Leukopenia	71 (66.36)	48 (44.86)	29 (17.6)	12 (7.3)		
Cytokine release syndrome	74 (69.16)	0	119 (72.1)	1 (0.6)	71 (57.7)	0
Neurotoxic event	1 (0.93)	0	24 (14.5)	1 (0.6)	4 (3.4)	0
Infections and infestations	81 (75.7)	46 (42.99)	126 (76.4)	74 (44.8)	86 (69.9)	49 (39.8)
Tumor Lysis Syndrome	1 (0.93)					

- mpe e E cacy
  -



F182112 is 2+2 Symmetric Format
Without ADCC and CDC ac ity



Contact: Zhenyu Li, lizhenyu@vip.lunan.cn

-
-
-

y c Pep

- **Oral Cyclic Pep des**

- **JNJ-2113 (ic r kinra) and MK-0616**



Lead Program – SG-6001

- **SG-600 Oral Cyclic Pep de PCSK9 Inhibit**
- **Indica ns**

- **Key P nts**
  -
  -
  -
  -
  -

Efficacy study in mice (intraperitoneal injection)

Dosage: 1mg/kg; 5 mice per group are intraperitoneally injected daily for 10 consecutive days





MEDICILON

PEG BIO

Innovation for Health

-
-
-

Tandem Expression of PEP es (TE-PEP®) orm

- Design Pep de Sequence
- High-level C nsistent Manu acturing Pep API thr ugh Tandem Expressi
  -
  -
- Mature Drug Delivery
  -
  -

Lead Program – PN20

- PN2
- Indica ns
  -
  -
  -
- PCT Patent

Phase Ia PLT count, s dose





Phase Ib in CIT pa ents, repeated doses





D sage (g/kg)	Cycle 1			Cycle 2		
	×	×	×	×	×	×

Phase I ic H ights

- d sa ety pr le
- AD

Phase Ib in CLDT pa ents, s dose



E cacy

×

- 0.5 g/kg
- 0.75 g/kg

P ic Mi stones

-
-



Contact: Peng He, hepeng@rnd.diao.com

Migraine Treatment Landscape

- Migraine is a prevalent neurological disorder, which is characterized by recurrent, moderate to severe unilateral pulsatile headaches.
- Faster pain relief remains an unmet need for migraine patients.
- Calcitonin gene-related peptide (CGRP) and its receptor are clinical approved targets for pain alleviation.
- ZAVZPRET, the first and only CGRP receptor antagonist nasal spray with frequently adverse events- [% ZAVZPRET vs % placebo]

Outstanding Pr RT-064040







- PRT-064040 exhibited better inhibitory activity (blocking CGRP-CGRP receptor activation) and higher binding affinity with CGRP receptor than Zavegepant (ZAZPRET).
- The permeability enhancer in PRT-064040 formulation promoted a higher systemic exposure (AUC) and faster absorption (Tmax).
- PRT-064040 displayed more sustainable efficacy than Zavegepant in a Cynomolgus hCGRP-induced dermal blood model, even at lower dose (lower plasma exposure).

Drug	Clinic Study	Dose	Common Adverse Drug Reaction	
			Dysgeusia	Nasal discomfort
PRT-064040*	Health subjects SAD	Dose 1	0	0
		Dose 2	0	0
		Dose 3	0	0
		Dose 4	0	0
		Dose 5	0	0
		Dose 6	0	0
	Health subjects MAD	Dose 5/7d	0	0
Zavegepant	Health subjects SAD	0.1~40 mg	2.8%	/
	Health subjects SAD	5~40 mg/14d	66.1%	10.7%
	BHV3500-301 Study	10 mg	21%	4%
	BHV3500-201 Study	5 mg	13.9%	1.3%
		10 mg	13.5%	1.3%
		20 mg	16.1%	5.2%
	BHV3500-202 Study	10 mg/52wks	39.1%	10.3%

*: Derived from unblinded data.

- PRT-064040 was well-tolerated and no dysgeusia reported in a completed Phase I study [NCT07016516]. The safety and PK support clinical advancement [CTR20254825]

[redacted]

-
-
-

◆ **HY-0902**

Indica

Di eren n

Phase II

Phase III

◆ **HY-1012**

Indica ns
Di eren n



BIOTECH

Synthe etha ity

- Synthe lethali
- Key Featur



Lead Program - YY2201

- YY2201 ATRi
- Indica
- Di eren a



- Preclinical Highligh
- Planned Clinical Milest



Revolutionize Biomanufacture – CelMo™: A virtual cell model for cellular control with tunable precision

Introduction

In Biomanufacutring, increasing productivity without triggering stress, metabolic imbalance, or quality drift remains a major challenge. **CelMo™**, our AI-driven Virtual Cell platform, addresses this by integrating multi-omics data with large-scale literature mining to identify high-value, druggable, and novel control points in cell biology.

CelMo™ models how cells respond to different nutrients, stresses, and perturbations, revealing levers that improve viable cell density, productivity, and metabolic stability. This enables gene target discovery and molecule design to act on the targets that deliver higher, more consistent, and scalable performance across manufacturing systems — keeping cells in an optimized productive state without changing production by a new cell line, cell line gene editing, or cell adaptation.

Method



CelMo: A Virtual Cell Platform For Target discovery and generation



Case CelMide s Gene targets enhance CHO cells ra pr uc

- Gene targets simulation outcome and prediction summary by CelMo

Knockout Type	Gene(s) Knocked Out	Predicted Effect	Likelihood Score	Shortlisted
Single Gene	Gene 1	↑ BCAA, ↑ mTORC1, ↑ productivity	0.72	Yes
Single Gene	Gene 2	↑ BCKA, ↓ redox efficiency	0.55	No
Single Gene	.....	↓ BCAA import, ↓ mTORC1	0.43	No
Double Gene	Gene 1 + Gene 2	↑ BCAA retention, ↑ productivity	0.84	Yes
Double Gene	.....	↑ cytosolic BCAA, mixed effects	0.68	No

- Wet lab validation on the gene target identified by CelMo (Gene 1 KO)









In vivo efficacy





Summary

Binding Prediction Accuracy
<1 kcal/mol error, 50% more accurate than traditional docking reducing wet-lab failure rates

Efficiency
>30% increase in generation efficiency

CELMO

Target Identification
Accelerates and improves early-stage pipeline decisions; captures non-obvious targets

Interaction Modeling
Intelligently propose gene targets and simulate outcome with

preserving the key interactions required for efficacy

User Experience
Virtual screening of 100,000 molecules/day allowing rapid iteration and feedback in molecule optimization

Contact: ling.wu@chemtbio.com; jie.sun@chemtbio.com

-
-
-

CD36 Deriva Pep orm

- **Mechani**
  -
  -
  - $CD36^{93-110}$
- **Preclinical Highligh**
  -
  -
  -
  -
  -
  -
- **CMC Highligh**
  -
- **Clinical Milest**
  -
  -

Contact: James Zhenhua Lin, linzh@huitaicn.com

MEDICILON

壹宸生物
Yi Chen Bio

Company Introduc on

(h p chenbi tech.c)

bispeci c an ies,
bispeci c an -drug c jugates, epit -directed cl nal
an ies l ng- g pr tein therapeu cs



Lead Programs

- **AF29 (A First-in-Class, Selec ve IL-1 Signaling Bl cker)**
  -
  -
  -
  -
  -
  -
  -



- **LTP0521 (A Best-in-Class, GLP-1/GIP/GCG/FGF-21 Quad-Ag nist)**
  -
  -
  -
  -
  -
  -
  -



- **M iT (M valent Bi-Targe An y)**
  -
  -
  -
  -
  -
  -
  -



YAFO

Contact: contact@yichen-bio.com

BIOTECH

Mechanism:

- **Mechani**

Key Feature

Lead Program - RDc001

- **RDc001 STAT3i**
- **Indica**

  Di eren a

Preclinical Highlight

Lead Program – SBC003

- SBC003 a gr undbreaking small m lecule p sed t rede ne treatment neur nal dis rders thr ugh its unique dual ac n r pr te and neur -rescuing.
- M upp ted by 20+ in-viv and in-vitr studies, SBC003 acts thr ugh three synergized dis nct targets/pathways t pr tect and rescue neur ns— ering a uni ed s acr s re nal and brain dis rders.
- Indica ns Re ni Pigment a (RP), dry macular degenera n (dry AMD), p c atr phy, Str ke, AD, PD etc.ze

Secukinumab

Indica

Secukinumab

D sage F

umab

Indica

Pembr umab

Indica

Pembr izumab

D sage F

Manu acturing Facili

MEDICILON

Website: www.medicilon.com

Email: marketing@medicilon.com

USA: 20 Maguire Road, Suite 103, Lexington, MA 02421, USA

China: 585 Chuanda Road, Pudong, Shanghai, 201299, China